Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 20/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7826642 | 0.99 | GNRHR (0.84) | GNRHRMEN1KMT2A | |
| SCHEMBL6545383 | 0.92 | GNRHR (1.00) | GNRHRMEN1KMT2A | |
| SCHEMBL7006717 | 0.92 | GNRHR (0.89) | GNRHRMEN1KMT2A | |
| SCHEMBL7828327 | 0.92 | GNRHR (1.00) | GNRHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7827346 | 0.91 | GNRHR (0.99) | GNRHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7498171 | 0.91 | GNRHR (0.88) | GNRHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7826617 | 0.91 | GNRHR (0.99) | GNRHRMEN1KMT2A | |
| SCHEMBL7006144 | 0.90 | GNRHR (1.00) | GNRHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7497376 | 0.90 | GNRHR (0.99) | GNRHRMEN1KMT2A | |
| SCHEMBL7833581 | 0.89 | GNRHR (0.89) | GNRHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116522-A1 | Medicinal solutions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1393747-A1 | PREVENTIVES/REMEDIES FOR ALZHEIMER'S DISEASE | Takeda Chemical Industries, Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| US-20040034039-A1 | Solid preparations | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| US-20040023987-A1 | Sustained release compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1374855-A1 | MEDICINAL SOLUTIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-20030134863-A1 | Preventives/remedies for alzheimer's disease | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1319409-A1 | SOLID PREPARATIONS | Takeda Chemical Industries, Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
| EP-1291023-A1 | SUSTAINED RELEASE COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2003-03-12 | — | — | EP | disclosed |
| US-6329388-B2 | GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; USEFUL FOR PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES, E.G., SEX HORMONE-DEPENDENT CANCERS (E.G., PROSTATIC CANCER, UTERINE CANCER, BREAST CANCER, PITUITARY TUMOR) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6297255-B1 | GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| US-6262267-B1 | HAS GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; USEFUL FOR PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES, E,G., SEX HORMONE-DEPENDENT CANCERS E.G., PROSTATIC CANCER, UTERINE CANCER, BREAST CANCER, PITUITARY TUMOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-17 | — | — | US | disclosed |
| US-20010001104-A1 | Thienopyridine compounds, their production and use | FURUYA SHUICHI (JP) | 2001-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134863-A1 | Preventives/remedies for alzheimer's disease | ACHE, GNRHR, PSEN1 | GNRHR 2/4885MEN1 477/4885KMT2A 1190/4885 |
| US-20040023987-A1 | Sustained release compositions | NGLY1, GHSR, GHRHR | GNRHR 46/4885MEN1 710/4885KMT2A 4627/4885 |
| US-20010001104-A1 | Thienopyridine compounds, their production and use | PRLHR, PGR, GNRHR | GNRHR 3/4885MEN1 517/4885KMT2A 446/4885 |
| US-20040034039-A1 | Solid preparations | GYS1, GYS2, SI | GNRHR 3501/4885MEN1 3398/4885KMT2A 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.